Here's Why Alkame Holdings, Inc. Jumped 40% Last Week…And Why More
Is Expected (ALKM)
April 12, 2021 -- InvestorsHub NewsWire -- via Benzinga --
Investors in Alkame Holdings, Inc. (OTCPINK: ALKM) were
met with a more than 40% increase last week. The jump comes as
investors evaluate several deals that could create a
revenue-generating surge later this year. Since April 5th, shares
have seen steady accumulation, closing the week near a level not
seen in almost two months. In fact, last Friday’s closing price of
$0.0035 is targeting highs for the year set back in February and
adds to the already staggering 483% year-to-date
increase.
The run appears to have started ahead of a planned April update
from PAO Group, Inc. (OTC Pink: PAOG) about
its CBD-based nutraceuticals program that includes ALKM as its
packing and logistics partner. Investors look particularly
interested in how PAOG’s plan to accelerate its launch date for two
nutraceutical assets can impact ALKM’s 2021 revenues. Obviously,
the calculation, based on the 40% share price increase, is bullish
and has put ALKM stock in play. Better still, if PAO Group hits its
targets, Alkame shares could be in store for an exponential run
higher.
Here’s why:
Value Through West Coast Co-Packer. Inc.
Subsidiary
Alkame Holdings owns a value driver that is inking deals. In
fact, several potentially lucrative deals made through its
wholly-owned subsidiary West Coast Co-Packer, Inc. could generate
multiple near-term revenue streams. And those deals extend beyond
those made with PAO Group.
Thus far, in 2021, West Coast Co-Packer, Inc. signed a
development and production agreement with Shmellins Market, LLC.,
is enhancing its relationship with Puration, Inc. (OTC
Pink; PURA) and is
capitalizing on a potentially enormous opportunity by distributing
a potential best-in-class hand sanitizer, Handout
Protection, to meet substantial demand created by the ongoing
COVID-19 pandemic.
The deal to distribute Handout
Protection clearly attracted investor’s attention. That
announcement sent shares soaring by more than 315% in February
after West Coast Co-Packer received an initial purchase order
for Handout Protection hand sanitizer and wash
combo single-use packets. That agreement came through its Canadian
Personal Protection Equipment (PPE) distributor, TheraProducts
Canada, Inc. Investors expect substantial returns from the deal,
especially with the product’s potential best-in-class COVID-19
bacteria-killing ability.
The better news is that the product could turn into a long-term
revenue driver for the company, with PPE products expected to
remain in high demand for public and private sector use. The niche
for Handout Protection is that, unlike some
competing products, it shows effectiveness in killing known
COVID-19 strains and the new coronavirus variants known to spread
50% quicker than COVID-19. Perhaps more importantly, it’s also one
of the few portable hand wash and sanitizer packets that allow
people to wash and sanitize their entire hand.
That could help make the product a favorite choice among medical
professionals. Why? Because a single package allows users to clean
their palms, the tops and sides of the hands, fingers, under the
nails, and up to the wrist to fight and kill bacteria and germs.
It’s the only known single-use sanitizer that offers such a
comprehensive cleaning.
Better still, despite the encouraging signs that the pandemic’s
grip on the nation is loosening, it’s unlikely that demand for
effective single-use sanitizing and germ-killing products will
decline. In that respect, it’s excellent news for ALKM. And meeting
substantial long-term demand from thousands of potential clients
could translate into significant revenues for the remainder of the
year.
While that deal could fuel ALKM’s growth in the immediate term,
other agreements could help push the already impressive 483% YTD
gains higher throughout the remainder of this year.
Generating value Through Logistical
Expertise
Investors responded well to ALKM announcing its role as the
co-packer and logistics partner for PAO Group, Inc’s CBD
RELAX-RX nutraceutical product. That deal is accretive to
one already in place to co-pack and distribute PAO
Group’s, RespRx, a potentially game-changing
CBD-based nutraceutical targeting the treatment of Chronic
Obstructive Pulmonary Disorder (COPD).
In fact, news of that
partnership sent shares soaring as far back as February,
with investors evaluating the
impact RespRx could have on revenues. Now,
with CBD RELAX-RX added to the mix, expectations
are even higher for revenues to spike later this year. Importantly,
not only is the product targeting a massive depression and anxiety
market, but PAO also expects to have the product ready for launch
as early as the third quarter of this year. Better still, with PAO
Group working with a contract research organization (CRO),
Veristat,
both RespRx and RELAX-RX could
accelerate through the development, approval, and marketing
process.
The excellent news is that the two products could come to the
market at a time when investors are again paying attention to the
massive and still emerging CBD-based treatment sector. And
positioning ahead of the planned release could help ALKM shares to
surge. Notably, for ALKM, the rewards can be substantial.
In fact, if PAO Group earns even a small piece of a combined $20
billion market opportunity from its products, ALKM could experience
massive growth from being its logistics partner. And not only are
both treatment markets expected to nearly double by 2025, which
also enhances Alkame’s potential earnings, but ALKM can also
benefit as the logistics partner from other CBD-based therapeutics
in mid to late-stage development with partner companies.
Its co-packing deal with Puration, Inc. could be the most
near-term catalyst.
A Better CBD-Infused
Water, EVERx
Again, through its wholly-owned subsidiary, West Coast
Co-Packer, Inc., ALKM announced an expansion of its partnership
with Puration, Inc. as the bottler of EVERx
CBD-infused Sports Water. That product generated sales of
roughly $2 million in 2019. In Q4, Puration guided that revenues in
2020 will likely surpass $2 million, with sales momentum expected
to increase in 2021. Those results are expected this month. The
takeaway is simple- growth for EVERx translates
to increased revenues for ALKM. Thus, the expected sales update
from Puration could have a positive impact on ALKM’s
valuation.
Better still, the two are capitalizing on additional market
opportunities. Last month, ALKM said it is collaborating to bring
to market multiple new CBD-infused consumer products, including a
CBD-infused liquid sugar and a CBD pet food supplement. Other
development-stage products include CBD-infused consumer products
and hemp-derived beverages and edibles.
Notably, these products target a substantial rise in consumer
demand, evidenced by CBD-based products flying off the shelves as
millions of users support the compound’s effectiveness in treating
a variety of conditions.
The sum of the parts of ALKM could lead to a breakout year.
Multiple Shots On Revenue-Generating
Goal
The best-case scenario for ALKM in 2021 is that they succeed in
helping to facilitate the launch of multiple products to market in
billion-dollar categories. However, their current deals should not
be underappreciated by investors, either. In fact, combining the
impact from sales of EVERx and Handout
Protection on their own could provide fuel for ALKM to
deliver record-breaking performance.
Also, keep in mind that ALKM could drive its value higher
through ownership of more than ten subsidiaries, strengthening the
investment proposition through exposure to multiple market sectors.
Those subsidiaries not only spread risk but also create additional
opportunities.
Therefore, don’t consider ALKM an exclusive play on future
opportunities in the CBD market. Instead, focus on the programs
that could generate massive value this year. Updates from at least
two are expected soon, and both could influence meaningful gains in
the stock price. Better still, with the back half of 2021 setting
up for ALKM to benefit from multiple shots on goal through its
existing partnerships, the best could be yet to come.
Thus, at these levels, the stock price could be exposing a
massive investment opportunity.
Disclaimers: Hawk Point Media is responsible for the
production and distribution of this content. Hawk Point Media is
not operated by a licensed broker, a dealer, or a registered
investment adviser. It should be expressly understood that under no
circumstances does any information published herein represent a
recommendation to buy or sell a security. Our reports/releases
are a commercial advertisement and are for general information
purposes ONLY. We are engaged in the business of marketing and
advertising companies for monetary compensation. Never invest in
any stock featured on our site or emails unless you can afford to
lose your entire investment. The information made available by
Hawk Point Media is not intended to be, nor does it constitute,
investment advice or recommendations. The contributors may buy and
sell securities before and after any particular article, report and
publication. In no event shall Hawk Point Media be liable to any
member, guest or third party for any damages of any kind arising
out of the use of any content or other material published or made
available by Hawk Point Media, including, without limitation, any
investment losses, lost profits, lost opportunity, special,
incidental, indirect, consequential or punitive damages. Hawk Point
Media was compensated three-thousand-five-hundred-dollars by wire
transfer to produce research, video, email, newsletters, and
editorial commentary for Alkame Holdings, Inc. by a third party.
Past performance is a poor indicator of future performance. The
information in this video, article, and in its related newsletters,
is not intended to be, nor does it constitute, investment advice or
recommendations. Hawk Point Mediastrongly urges you conduct a
complete and independent investigation of the respective companies
and consideration of all pertinent risks. Readers are advised to
review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider
reports, Forms 3, 4, 5 Schedule 13D.
The Private Securities Litigation Reform Act of 1995
provides investors a safe harbor in regard to forward-looking
statements. Any statements that express or involve discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, goals, assumptions or future events or performance are
not statements of historical fact may be forward looking
statements. Forward looking statements are based on expectations,
estimates, and projections at the time the statements are made that
involve a number of risks and uncertainties which could cause
actual results or events to differ materially from those presently
anticipated. Forward looking statements in this action may be
identified through use of words such as projects, foresee, expects,
will, anticipates, estimates, believes, understands, or that by
statements indicating certain actions & quote; may, could, or
might occur. Understand there is no guarantee past performance will
be indicative of future results.Investing in micro-cap and growth
securities is highly speculative and carries an extremely high
degree of risk. It is possible that an investors investment may be
lost or impaired due to the speculative nature of the companies
profiled.
Media Contact
Company Name: Hawk Point Media
Contact Person: KL Feigeles
Email: editorial@hawkpointmedia.com
City: Miami Beach
State: Florida
Country: United States
Website: https://www.greenlightstocks.com
Source - https://www.benzinga.com/pressreleases/21/04/ab20576474/heres-why-alkame-holdings-inc-jumped-40-last-week-and-why-more-is-expected-alkm
Other stocks on the move include
RGBP and
WPMLF
SOURCE:
Benzinga
Western Pacific Minerals (CE) (USOTC:WPMLF)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Western Pacific Minerals (CE) (USOTC:WPMLF)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
